Welcome to the ARLG Newsletter! Here, you will receive important updates from ARLG regarding recent events, grants, publications, and the committees that help us work toward our mission: to prioritize, design, and execute clinical research that will impact the prevention, diagnosis, and treatment of infections caused by antibiotic-resistant bacteria.

Get Involved with ARLG

ARLG continuously accepts proposals for clinical studies designed to prevent, diagnose, treat, or eradicate antibiotic-resistant bacterial pathogens. We also award grants and fellowships to qualified investigators. If you are interested in getting involved with ARLG, apply now or contact us for more information.

Submit a Proposal  Contact Us

News

ARLG Spotlight - Michael Woodworth, MD, MSc, Emory University Silver Pear Mentoring Award Recipient

Michael Woodworth, MD, MSc, Vice-Chair of ARLG Mentoring Committee and former ARLG fellow, has been honored with the Shanthi V. Sitaraman Silver Pear Mentoring Award for Research by Emory University School of Medicine. This accolade recognizes his exceptional mentorship to early-career mentees, particularly Ahmed Babiker, an ARLG Early Faculty Seedling Award recipient. Dr. Woodworth's research focuses on microbiome therapeutics, such as fecal microbiota transplantation (FMT), for eradicating multi-drug resistant organisms in the intestines.
Tori Kinamon Featured in BBC StoryWorks’ Film “Race Against Resistance”

ARLG Innovations Working Group Member Tori Kinamon is featured in the BBC StoryWorks film "Race Against Resistance: The Life and Death Struggle to Save Antibiotics." The documentary was funded by the AMR Action Fund with support from Shionogi, Pfizer, and MSD. It addresses the global threat of antibacterial resistance (AR) and includes personal stories of AR survivors, highlighting Kinamon's own journey from MRSA survivor to MD Candidate and infectious diseases researcher.

DOTS Study Hits Enrollment Milestone

The Dalbavancin as an Option for Treatment of *Staphylococcus aureus* Bacteremia (DOTS) Study has successfully enrolled 200 participants with *S. aureus* bloodstream infections, meeting its enrollment target in July 2023. *S. aureus* infections are often life-threatening and antibiotic-resistant, typically requiring a prolonged IV antibiotic treatment. Dalbavancin, a long-acting antibiotic, offers a unique treatment approach, administered as two IV doses one week apart, eliminating the need for central catheters. The study, led by ARLG Primary Investigator Thomas Holland, MD, aims to evaluate Dalbavancin's safety and efficacy in treating *S. aureus* bacteremia, potentially transforming its management.

ARLG Partners with Biomeme on Study of New Diagnostic Tool to Tackle AR

In support of the Scientific Agenda to prioritize novel diagnostics, ARLG is partnering with
Biomeme on the RADICAL 510(k) Study. This study aims to assess Biomeme’s new test that detects bacterial or viral infections by analyzing host gene expression in blood. Quick and accurate diagnosis can help physicians tailor effective treatment plans, reducing unnecessary antibiotic use and improving stewardship. ARLG Primary Investigators Gayani Tillekeratne, MD and Thomas Holland, MD are leading the study, and this collaboration aims to enhance diagnostic tools in the fight against antibacterial resistance.

SHRECG Study Summary Now Available

A lay summary of results for the Study of Highly Resistant Escherichia Coli (SHRECG) is now available! SHRECG compared the clinical outcomes of patients with E. coli blood infections that were susceptible to the antibiotic ceftriaxone to those of patients with ceftriaxone-resistant E. coli infections. E. coli infections are one of the most common types of bacterial infections found in the bloodstream, and ceftriaxone is commonly used to treat such infections. The number of E. coli bloodstream infections that are resistant to ceftriaxone in the United States has grown.

Clinical outcomes of 300 adult and pediatric participants across the U.S. were described in the study using the Desirability of Outcome Ranking (DOOR) method, where outcomes ranged from alive with no events to death within 30 days after diagnosis. Results showed that participants with ceftriaxone-resistant E. coli infections had overall worse clinical outcomes than participants with ceftriaxone-susceptible infections. Participants with ceftriaxone-resistant E. coli infections tended to be less healthy at the onset of the study though, which is thought to be the primary reason for the worse outcomes. These findings indicate that being infected with a ceftriaxone-resistant E. coli may impact quality of life more so than infection with ceftriaxone-susceptible E. coli.

Events
IDWeek 2023: Featured ARLG Sessions and Posters

It's that time of year again! IDWeek 2023 is here and many of ARLG's top leaders and experts are featured, discussing the latest AR topics.

Don’t miss Sara Cosgrove, MD, ARLG member and Director of the Johns Hopkins Hospital Department of Antimicrobial Stewardship Program, as the SHEA Lectureship featured speaker Oct. 13 from 4:45 – 6:00 p.m. The SHEA Lectureship Award is given in recognition of a senior investigator’s career contributions to healthcare epidemiology and infection prevention and control.

Whether you are attending the event virtually or in person, use our guide of sessions and posters to plan ahead.

Learn more

Study Milestones

View recent ARLG study updates.

<table>
<thead>
<tr>
<th>FAST</th>
<th>Fast Antibiotic Susceptibility Testing for gram-negative bacteremia</th>
<th>Site Start-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>OPTIMIZE-GNI</td>
<td>Optimization of Beta-lactam Dosing in Critically-Ill Patients with Suspected or Documented Antimicrobial Resistant Gram-Negative Infections with Cystatin C</td>
<td>Protocol Development</td>
</tr>
<tr>
<td>RADICAL 510(k)</td>
<td>Rapid Diagnostic in Categor izing Acute Lung Infections</td>
<td>Protocol Finalized-Start-up</td>
</tr>
<tr>
<td>REPROCESS</td>
<td>Racial DisparitiEs in CarbaPenem-Resistant Bacteria: Epidemiology and OutComEs of US PatientS</td>
<td>Study Design</td>
</tr>
</tbody>
</table>
ESCAPED Emergin Staphylococcus aureus and Current Antimicrobial Patterns in Emergency Departments

Study Design

DARMA Disparities in Antibacterial Resistance: A Series of Meta-Analyses

Study Design

Go to the ARLG Studies page for more milestones and updates!

Learn More

Recent Publications

View the following recent ARLG publications.


Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T,